The prospective TAILORx trial 12 and WSG Plan B trial 14 have shown the predictive value of RS on ACT in HR+/HER2- early breast cancer, supporting that 21-gene RS can be incorporated into traditional clinical-pathological factors for ACT decision-making. This evidence concerns the gene ERBB2 and breast cancer.